identified the oncogenic potential of N-glycosylation sites on the extracellular C-terminal part of MUC16 in ovarian cancer, showing that monoclonal antibodies targeting these sites significantly inhibit ovarian cancer cell invasion and growth of xenograft tumors with MUC16, all driven by an MGAT5-dependent mechanism (149). Here, MUC16 is linked to ovarian carcinoma.